CS
OTLK icon

Credit Suisse’s Outlook Therapeutics OTLK Stock Holding History

Credit Suisse’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– -$5 – 3592
2022
Q4 		– Sell
-34
Closed -$740 – 3822
2022
Q3 		$1K Buy
34
+33
+3,300% +$767 ﹤0.01% 3895
2022
Q2 		$0 Buy
+1
New +$29 ﹤0.01% 4199
2020
Q3 		– Sell
-2,500
Closed -$65K – 4096
2020
Q2 		$65K Buy
+2,500
New +$44.6K ﹤0.01% 3861

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Credit Suisse's OTLK Position: Q1 2023 in Review

Credit Suisse held its Outlook Therapeutics (OTLK) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3592.

Credit Suisse first reported a position in OTLK in Q2 2020 and has held it in 3 quarters since. The position peaked at $65K in Q2 2020. 82 funds tracked by Wall St. Rank hold OTLK as of Q1 2023.

  • Credit Suisse held 0 shares of Outlook Therapeutics worth $0 as of Q1 2023.
  • Credit Suisse left its Outlook Therapeutics share count unchanged in Q1 2023.
  • Outlook Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2023, its #3592 holding.
  • Credit Suisse first reported a position in Outlook Therapeutics in Q2 2020 and has held it in 3 quarters since.
  • Credit Suisse's Outlook Therapeutics position peaked at $65K in Q2 2020.
  • 82 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.